Actinium Pharmaceuticals presents first-in-human ATNM-400 data in prostate cancer
ATNM•Actinium Pharmaceuticals will present early Phase 1 data on ATNM-400 in metastatic castration-resistant prostate cancer at EANM in Vienna, alongside preclinical lung cancer research.
1. Study presentations
Actinium Pharmaceuticals will present early Phase 1 data from its ongoing first-in-human ATNM-400 study in metastatic castration-resistant prostate cancer at EANM in Vienna. The study evaluates an imaging counterpart to guide development and dosing of the HER3-targeted radiotherapy beyond PSMA-directed treatment. A separate presentation will cover preclinical lung cancer studies testing ATNM-400 alone or with targeted therapies, supporting potential expansion across solid tumors.
